Morgans names more of the best ASX 200 shares to buy in May

MotleyFool05-09

The team at Morgans has been busy picking out its best ASX 200 share ideas for May. The first two ASX 200 shares we looked at can be found here. Read on for three more picks: CSL Ltd (ASX: CSL) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434270920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-09 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2434270920","market":"us","top_or_hot":-1,"title":"Morgans names more of the best ASX 200 shares to buy in May","media":"MotleyFool","content":"<div>\n<p>The team at Morgans has been busy picking out its best ASX 200 share ideas for May.\nThe first two ASX 200 shares we looked at can be found here. Read on for three more picks:\nCSL Ltd (ASX: CSL)\n...</p>\n\n<a href=\"https://www.fool.com.au/2024/05/09/morgans-names-more-of-the-best-asx-200-shares-to-buy-in-may/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgans names more of the best ASX 200 shares to buy in May</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgans names more of the best ASX 200 shares to buy in May\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-09 05:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/05/09/morgans-names-more-of-the-best-asx-200-shares-to-buy-in-may/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The team at Morgans has been busy picking out its best ASX 200 share ideas for May.\nThe first two ASX 200 shares we looked at can be found here. Read on for three more picks:\nCSL Ltd (ASX: CSL)\n...</p>\n\n<a href=\"https://www.fool.com.au/2024/05/09/morgans-names-more-of-the-best-asx-200-shares-to-buy-in-may/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD.AU","symbol_name":"Resmed DRC","start_time":0,"source_url":"https://www.fool.com.au/2024/05/09/morgans-names-more-of-the-best-asx-200-shares-to-buy-in-may/","article_id":"2434270920","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434270920","pubTimestamp":1715202180,"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"The team at Morgans has been busy picking out its best ASX 200 share ideas for May.The first two ASX 200 shares we looked at can be foundhere. Read on for three more picks:. Morgans thinks that this biotech giant would be a great option this month. Especially given its attractive valuation and strong earnings per share growth outlook. It said:. While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.Morgans has an add rating and $35.60 price target on the company's shares.","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD.AU":"Resmed DRC","BK7105":"多领域控股","BK7007":"医疗保健设备","BK7508":"医药生物股","BK7067":"生物科技","BK7511":"ESG概念","CSL.AU":"CSL LIMITED","SOL.AU":"WASHINGTON H. SOUL PATTINSON","BK7083":"煤与消费用燃料","BK7501":"新冠治疗股"},"translate_title":"摩根士丹利列出了更多5月份可以购买的ASX 200指数最佳股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1,"RMD.AU":1,"SOL.AU":1},"content_text":"The team at Morgans has been busy picking out its best ASX 200 share ideas for May.\nThe first two ASX 200 shares we looked at can be found here. Read on for three more picks:\nCSL Ltd (ASX: CSL)\nMorgans thinks that this biotech giant would be a great option this month. Especially given its attractive valuation and strong earnings per share growth outlook. It said:\n\nWhile shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.\n\nThe broker has an add rating and $315.35 price target on CSL's shares.\nResMed Inc. (ASX: RMD)\nAnother ASX 200 share that Morgans is tipping as a strong buy is sleep disorder treatment company ResMed.\nIts analysts feel that concerns over weight loss drugs disrupting its market are unwarranted. As a result, it believe ResMed's long-term growth outlook remains very positive. It said:\n\nWhile weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.\n\nThe broker has an add rating and $34.11 price target on its shares.\nWashington H Soul Pattinson & Company Ltd (ASX: SOL)\nA third ASX 200 share that is on Morgans' best ideas list this month is investment house Soul Patts.\nThe broker likes the company due to its positive long term track record and diversified business. It explains:\n\nSOL's investment portfolio includes a diversified pool of assets ranging from listed equities (both large cap and emerging companies), private equity, property and structured yield. On a 20-year horizon, SOL's annualised TSR is 12.5% vs the All Ords accumulation index of 9%. SOL has a 20-year history of increased dividend distributions, with a 20-year CAGR of c.8%. In our view, SOL's management team continues to deliver both organic and inorganic growth over the long term. We continue to like the SOL story, particularly its track record of growing distributions.\n\nMorgans has an add rating and $35.60 price target on the company's shares.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434270920"}